אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - abacavir sulfate; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

ישראל - אנגלית - Ministry of Health

taro international ltd, israel - abacavir; lamivudine - film coated tablets - lamivudine 300 mg; abacavir 600 mg - lamivudine and abacavir - abacavir lamivudine taro is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults, adolescents and children weighing at least 25 kg.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: macrogol 8000; sunset yellow fcf aluminium lake; titanium dioxide; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; hypromellose; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; titanium dioxide; croscarmellose sodium; macrogol 8000; colloidal anhydrous silica; sunset yellow fcf aluminium lake; magnesium stearate - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sunset yellow fcf aluminium lake; macrogol 8000; hypromellose; titanium dioxide; magnesium stearate; croscarmellose sodium; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: sunset yellow fcf aluminium lake; magnesium stearate; microcrystalline cellulose; macrogol 8000; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; hypromellose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

remedyrepack inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

avera mckennan hospital - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 300 mg

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - kivexa tablets are a combination of two nucleoside analogues (abacavir and lamivudine). kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

zydus lifesciences limited - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine is contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital